The use of humanised monoclonal antibodies to inhibit growth factors essential to tumour growth has proved a very successful treatment. However, not all patients will respond to this treatment - a variety are needed to ensure that the most people possible are able to receive effective treatment.
Human growth hormone expression in breast cancer has been associated with reduced survival in patients. Dr Perry is going to investigate whether a monoclonal antibody could be developed to target this hormone (rather than just the growth factors), reducing likelihood of recurrence.
Funding was provided by a tripartite partnership with BCFNZ, the Health Research Council of New Zealand (HRC) and Breast Cancer Cure (BCC).